CSRP2

Across TCGA pan-cancer cohorts, CSRP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CSRP2 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CSRP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CSRP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where CSRP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.834	0.627	.005	21	view →
LUAD	OS	Median	II,III,IV	0.768	0.406	.005	6	view →
LSCC	OS	Tertile	III,IV	0.441	0.839	.022	6	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	4	view →
GBM	OS	Tertile	All	0.718	0.831	.031	3	view →
UCEC	DFS	Median	All	0.929	0.794	.032	2	view →
CCRCC	OS	Median	II,III,IV	0.462	0.827	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CSRP2–HNSC (DFS)

Open the HNSC breakdown →